Home LiteratureArticle Details
PMID: 11854194 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Cross-protective immunity of mice induced by oral immunization with pneumococcal surface adhesin a encapsulated in microspheres.

Infection and immunity ·Vol. 70 ·No. 3 ·2002-03-00 ·Pages 1143-9

Seo JY, Seong SY, Ahn BY, Kwon IC, Chung H, Jeong SY

Abstract

The global use of a capsular polysaccharide-based pneumococcal vaccine has been limited because of serotype-specific protection and poor effectiveness in individuals with low immunocompetency. The mucosal immune system develops earlier in infants and lasts longer in the elderly than does the systemic immune system. Furthermore, mucosal immunization is beneficial for AIDS patients, because human immunodeficiency virus-infected subjects can develop normal mucosal antibody responses even in late clinical phases. For these reasons, we evaluated recombinant pneumococcal surface adhesin A (rPsaA) of Streptococcus pneumoniae in terms of cross-protective immune responses after oral delivery. Encapsulated rPsaA provided higher immunogenicity than naked rPsaA. Coencapsulation or codelivery of the cholera toxin (CT) B subunit (CTB) and CT also increased the immunogenicity of rPsaA. Cross-protective immunities against five strains of S. pneumoniae (types 4, 6B, 14, 19F, and 23F) were induced after oral immunization with microencapsulated rPsaA. Lung colonization and septicemia caused by the five serotypes were significantly inhibited by oral immunization with microencapsulated rPsaA. These results suggest that rPsaA coencapsulated with CTB can be used as an oral vaccine to induce cross-protective immunity for the prevention of pneumococcal infection.

MeSH Terms
Adhesins, Bacterial/genetics,therapeutic use Administration, Oral Animals Antibodies, Bacterial/blood Antibody Specificity Bacterial Proteins Carrier Proteins/genetics,therapeutic use Cross Reactions Drug Compounding Female Lipoproteins/genetics,therapeutic use Membrane Transport Proteins Mice Mice, Inbred BALB C Pneumococcal Vaccines/genetics,therapeutic use Pneumonia, Pneumococcal/prevention & control Recombinant Proteins/therapeutic use Vaccination/methods Vaccines, Synthetic/therapeutic use
Chemicals
Adhesins, Bacterial Antibodies, Bacterial Bacterial Proteins Carrier Proteins Lipoproteins Membrane Transport Proteins Pneumococcal Vaccines PsaA protein, Streptococcus Recombinant Proteins Vaccines, Synthetic
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Seo Jun-Young
Biomedical Research Center, Korea Institute of Science and Technology, Seoul 136-791, Korea.
Seong Seung Yong
Ahn Byung-Yoon
Kwon Ick Chan
Chung Hesson
Jeong Seo Young
References (46)
46 references, click to expand
  1. Triggering the first line of defense.
    Science. 1994 Sep 9;265(5178):1522-4 PMID: 8079164
  2. Activation of tissue macrophages from AIDS patients: in vitro response of AIDS alveolar macrophages to lymphokines and interferon-gamma.
    J Immunol. 1985 Oct;135(4):2374-7 PMID: 3928746
  3. Novel pneumococcal surface proteins: role in virulence and vaccine potential.
    Trends Microbiol. 1998 Mar;6(3):85-7; discussion 87-8 PMID: 9582927
  4. Lack of age-associated immune dysfunction in mucosal-associated lymph nodes.
    J Immunol. 1981 Jun;126(6):2200-4 PMID: 6164724
  5. Crystallized dextran nanospheres with entrapped antigen and their use as adjuvants.
    J Immunol Methods. 1984 May 11;70(1):127-32 PMID: 6201561
  6. Protective immunity of microsphere-based mucosal vaccines against lethal intranasal challenge with Streptococcus pneumoniae.
    Infect Immun. 1999 Jul;67(7):3587-92 PMID: 10377143
  7. Biodegradable microspheres. III: some immunological properties of polyacryl starch microparticles.
    J Pharm Sci. 1986 Jul;75(7):697-701 PMID: 3489834
  8. Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae.
    Infect Immun. 2000 Feb;68(2):796-800 PMID: 10639448
  9. Carriage of pneumococci after pneumococcal vaccination.
    Lancet. 1996 Jul 27;348(9022):271-2 PMID: 8684225
  10. Pneumococcal disease: prospects for a new generation of vaccines.
    Science. 1994 Sep 2;265(5177):1385-7 PMID: 8073278
  11. Immunopotentiation of local and systemic humoral immune responses by ISCOMs, liposomes and FCA: role in protection against influenza A in mice.
    Vaccine. 1993 Oct;11(13):1302-9 PMID: 8296483
  12. Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae.
    Infect Immun. 1994 Dec;62(12):5683-8 PMID: 7960154
  13. Immunoreactivity of five monoclonal antibodies against the 37-kilodalton common cell wall protein (PsaA) of Streptococcus pneumoniae.
    Clin Diagn Lab Immunol. 1998 Mar;5(2):205-10 PMID: 9521144
  14. Sequence heterogeneity of PsaA, a 37-kilodalton putative adhesin essential for virulence of Streptococcus pneumoniae.
    Infect Immun. 1996 Dec;64(12):5255-62 PMID: 8945574
  15. Production of 5-15 microns diameter alginate-polylysine microcapsules by an air-atomization technique.
    Pharm Res. 1991 Mar;8(3):341-4 PMID: 2052521
  16. Anti-polysaccharide immunoglobulin isotype levels and opsonic activity of antisera: relationships with protection against Streptococcus pneumoniae infection in mice.
    J Infect Dis. 1995 Aug;172(2):562-5 PMID: 7622906
  17. Intestinal immune responsiveness in HIV-infected individuals.
    Adv Exp Med Biol. 1995;371B:1011-4 PMID: 7502741
  18. Potential of polymer microencapsulation technology for vaccine innovation.
    Vaccine. 1994 Jan;12(1):5-11 PMID: 8303941
  19. Impact of Streptococcus pneumoniae bacteremia and human immunodeficiency virus type 1 on oral mucosal immunity.
    J Infect Dis. 1995 Aug;172(2):566-70 PMID: 7622907
  20. Pneumococcal vaccines: history, current status, and future directions.
    Am J Med. 1999 Jul 26;107(1A):69S-76S PMID: 10451012
  21. Development of oral vaccines to stimulate mucosal and systemic immunity: barriers and novel strategies.
    Clin Immunol Immunopathol. 1995 Feb;74(2):127-34 PMID: 7828366
  22. Purification and immunogenicity of genetically obtained pneumolysin toxoids and their conjugation to Streptococcus pneumoniae type 19F polysaccharide.
    Infect Immun. 1991 Jul;59(7):2297-304 PMID: 2050399
  23. Novel mucosal immunization with polysaccharide-protein conjugates entrapped in alginate microspheres.
    J Control Release. 1998 Apr 30;53(1-3):215-24 PMID: 9741929
  24. A lavage technique allowing repeated measurement of IgA antibody in mouse intestinal secretions.
    J Immunol Methods. 1984 Feb 24;67(1):101-8 PMID: 6366063
  25. PREVENTION OF PNEUMOCOCCAL PNEUMONIA BY IMMUNIZATION WITH SPECIFIC CAPSULAR POLYSACCHARIDES.
    J Exp Med. 1945 Nov 30;82(6):445-65 PMID: 19871511
  26. Development of intestinal mucosal immunity in fetal life and the first postnatal months.
    Pediatr Res. 1992 Aug;32(2):145-9 PMID: 1508603
  27. Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae.
    Infect Immun. 2000 May;68(5):3028-33 PMID: 10769009
  28. Class-specific antibody response to pneumococcal capsular polysaccharides in men infected with human immunodeficiency virus type 1.
    J Infect Dis. 1988 Nov;158(5):983-90 PMID: 3183430
  29. Protection of mice against fatal pneumococcal challenge by immunization with pneumococcal surface adhesin A (PsaA).
    Microb Pathog. 1996 Jul;21(1):17-22 PMID: 8827703
  30. Controlled release microparticles for vaccine development.
    Vaccine. 1991 Oct;9(10):768-71 PMID: 1759495
  31. Chitosan and its use as a pharmaceutical excipient.
    Pharm Res. 1998 Sep;15(9):1326-31 PMID: 9755881
  32. Manipulation of intestinal immune responses against ovalbumin by cholera toxin and its B subunit in mice.
    Immunology. 1991 Jan;72(1):89-93 PMID: 1705237
  33. Characterization of a recombinant pneumolysin and its use as a protein carrier for pneumococcal type 18C conjugate vaccines.
    Infect Immun. 1995 Jul;63(7):2706-13 PMID: 7790088
  34. Contribution of serotype-specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae.
    Clin Exp Immunol. 1999 Dec;118(3):402-7 PMID: 10594558
  35. Biologically erodable microspheres as potential oral drug delivery systems.
    Nature. 1997 Mar 27;386(6623):410-4 PMID: 9121559
  36. Protection of infant mice from challenge with Streptococcus pneumoniae type 19F by immunization with a type 19F polysaccharide--pneumolysoid conjugate.
    Vaccine. 1994 Aug;12(10):875-8 PMID: 7975828
  37. Immune response following oral administration of cholera toxin B subunit to HIV-1-infected UK and Kenyan subjects.
    AIDS. 1994 Jun;8(6):779-85 PMID: 8086136
  38. Protection against vaginal SIV transmission with microencapsulated vaccine.
    Science. 1993 May 28;260(5112):1323-7 PMID: 8493576
  39. Pneumococcal polysaccharide immunization in infants and children.
    Pediatrics. 1978 Nov;62(5):721-7 PMID: 31592
  40. Impaired immunity to pneumococcal polysaccharide antigens in children with human immunodeficiency virus infection immunized with pneumococcal vaccine.
    Pediatr Infect Dis J. 1994 Oct;13(10):933-4 PMID: 7854897
  41. Phase variation in pneumococcal opacity: relationship between colonial morphology and nasopharyngeal colonization.
    Infect Immun. 1994 Jun;62(6):2582-9 PMID: 8188381
  42. Comparative efficacy of pneumococcal neuraminidase and pneumolysin as immunogens protective against Streptococcus pneumoniae.
    Microb Pathog. 1988 Dec;5(6):461-7 PMID: 3149709
  43. Immunosenescence and mucosal immunity.
    Lancet. 1993 Mar 27;341(8848):793-4 PMID: 8096004
  44. Systemic and mucosal protective immunity to pneumococcal surface protein A.
    Ann N Y Acad Sci. 1996 Oct 25;797:118-26 PMID: 8993356
  45. Limited diversity of Streptococcus pneumoniae psaA among pneumococcal vaccine serotypes.
    Infect Immun. 1997 May;65(5):1967-71 PMID: 9125591
  46. Oral immunization with influenza virus in biodegradable microspheres.
    J Infect Dis. 1993 Jan;167(1):84-90 PMID: 8418185
Article Info
Journal
Infection and immunity
Abbr.
Infect Immun
ISSN
0019-9567
DOI
10.1128/IAI.70.3.1143-1149.2002
Published
2002-03-00
Pages
1143-9
Language
English
Region
United States
NLM ID
0246127
PMCID
PMC127797
Subset
IM
External Links
PubMed source DOI: 10.1128/IAI.70.3.1143-1149.2002 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2